Apatinib, an orally active TKI that potently targets vascular endothelial growth factor receptor 2 (VEGFR2) and platelet-derived growth factor receptor, has been approved for the treatment of advanced gastric cancer refractory to two or more lines of prior chemotherapy (10). This evidence concerns the gene KDR and gastric cancer.